Table 2.

Prevalence and number of ACFs among the 3 subject groups stratified according to age and sex

 MaleFemale
<60 y60–69 y≥70 yTotal<60 y60–69 y≥70 yTotal
ACF prevalencea
Normal subjects
 Number of subjects896260211785242172
 Prevalence, %6274676751716761
Adenoma cases
 Number of subjects799294265294434107
 Prevalence, %8988959176828280
CRC cases
 Number of subjects153424739111333
 Prevalence, %939496951009110097
ACF number, bmean ± SD
Normal subjects2.6 ± 3.25.3 ± 7.14.6 ± 6.23.9 ± 5.61.8 ± 2.63.8 ± 5.05.0 ± 6.53.2 ± 4.7
Adenoma cases5.0 ± 5.56.8 ± 7.98.1 ± 8.06.7 ± 7.44.7 ± 5.93.8 ± 4.16.1 ± 7.84.8 ± 6.0
CRC cases8.7 ± 8.410.5 ± 7.410.0 ± 7.310.0 ± 7.510.9 ± 11.68.5 ± 9.311.8 ± 6.010.5 ± 8.7
P<0.001<0.001<0.001<0.001‡<0.0010.19<0.005<0.001c
  • aP < 0.001 and P < 0.001 (men and women, respectively), calculated using an age-adjusted logistic regression analysis for the 3 subject groups stratified according to sex.

  • bDifferences among the age-stratified subject groups (<60, 60–69, and ≥70 years) were analyzed using the Kruskal–Wallis test.

  • cAn age-adjusted linear regression analysis was conducted to evaluate the differences among the 3 subject groups stratified according to sex.